MEDIA RELEASE

For Immediate Release

Avellino Partners with Sugentech, Inc. to Distribute SGTi-flex COVID-19 IgG Antibody Test

Rapid immunochromatographic test kit received FDA Emergency Use Authorization on April 23, 2021

MENLO PARK, Calif. – (July 7, 2021) – Avellino Lab USA, Inc. (Avellino) and Sugentech, Inc., a bio- and nano- based technology and in-vitro diagnostic firm based in Korea, as part of their partnership agreement announced in August 2020, has begun distribution of Sugentech's SGTi-flex COVID-19 IgG antibody test in the US.

Sugentech received FDA Emergency Use Authorization (EUA) for the SGTi-flex COVID-19 IgG antibody test in April 2021. The test has shown 99 percent specificity individuals who areRT-PCR positive in clinical studies, with results available in 10 to 15 minutes. Antibody or serology tests look for antibodies in the blood to determine past infection, including for the virus that causes COVID-19, or if an individual has been vaccinated.

Along with Avellino's current AvellinoCoV2 COVID-19 test and Covid/Flu AvellinoCoV2 Respiratory test, Avellino is able to offer a number of pre- and post COVID-19 testing solutions as the SARS-CoV-2 virus continues to circulate and impact communities both in the US and globally.

As part of the agreement Avellino also plans to commercialize Sugentech's quantitative viral neutralization, enzyme-linked immunosorbent assay (ELISA) to determine the presence of protective antibodies against COVID-19.

"We are proud to partner with Sugentech to bring their rapid COVID-19 IgG antibody rapid test to the United States and as a great compliment to Avellino's current COVID-19 tests," says Avellino Head of US Operations Scott Korney. "Antibody tests continue to be an important way to track and potentially determine if an individual has had prior exposure to SARS-CoV-2, in particular in vulnerable populations, including nursing homes."

"Sugentech is pleased to partner with Avellino in making our EUA granted SGTi-flex COVID-19 IgG antibody test available in the United States," says JungEun (Joanna) Lee, Ph.D., Vice

President (CSO) of Sugentech. “COVID-19 knows no bounds, so the more we can make these valuable tests available, the sooner we can mitigate the effects of this life-threatening virus.”

About Avellino

Avellino Lab USA, Inc. is a global leader in gene therapy and molecular diagnostics at the forefront of precision medicine for eye care. With a long-term mission to develop personalized approaches to better health and disease management through genomics, the company is developing a transformative genetic diagnostics product pipeline, as well as genetic therapeutics leveraging CRISPR gene editing, to better manage and potentially cure inherited diseases. The company also developed the EAU-approved AvellinoSARS-CoV-2 RT-PCR diagnostic test to aid in COVID-19 pandemic testing efforts in the US, and was the third private company in the US to receive EUA for its COVID-19 test. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, China and the UK.

To learn more about Avellino, visit www.avellino.com.

About Sugentech

Sugentech, Inc. has established and offers fully-integrated diagnostic systems in South Korea. The company has accumulated various and robust bio- and nano- based technologies and has successfully commercialized a variety of in-vitro diagnostic products, including self-diagnostics home testing products (self-testing), point-of-care testing (POCT) products, and fully automated immunoblot systems for multiplex testing. The company also offers tests related to Covid-19, including a Covid-19 antigen test, a COVID-19/Influenza test, and a neutralizing efficacy assay and antibody test.

You can learn more about Sugentech at http://sugentech.com/main.php

Media Contact – Avellino
Angela Lapré
Angela.Lapre@Avellino.com
203.300.3865

# # #